The role of cangrelor in acute and high-risk PCI settings

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin (ASA) and oral P2Y12 inhibitors is standard for preventing thrombotic events post-percutaneous coronary intervention (PCI).
• Oral P2Y12 inhibitors have significant limitations in acute, high-risk PCI scenarios, including ST-elevation myocardial infarction (STEMI) with cardiogenic shock (CS) or cardiac arrest (CA).
• Factors like vomiting, altered physiology, ventilation, and hypothermia impair oral drug absorption, reducing antiplatelet efficacy and increasing ischemic risk in these critical patients.

Purpose of the Study:

• To review the role of intravenous cangrelor as an alternative antiplatelet strategy in acute and high-risk PCI settings.
• To highlight cangrelor's pharmacokinetic and pharmacodynamic properties that make it suitable for these challenging clinical scenarios.
• To summarize real-world evidence on cangrelor adoption and provide practical guidance for its use and transition to oral agents.

Main Methods:

• Review of pharmacokinetic and pharmacodynamic attributes of cangrelor.
• Synthesis of evidence from real-world studies on cangrelor utilization in contemporary practice.
• Development of a practical guide for cangrelor administration and post-PCI transition strategies.

Main Results:

• Cangrelor's pharmacokinetic and pharmacodynamic profile offers rapid onset and offset, ensuring predictable platelet inhibition.
• Real-world data demonstrate cangrelor's effective use in acute and high-risk PCI, addressing limitations of oral agents.
• Guidelines for cangrelor use and seamless transition to oral P2Y12 inhibitors are provided.

Conclusions:

• Intravenous cangrelor provides a valuable alternative to oral P2Y12 inhibitors in acute and high-risk PCI, particularly in STEMI patients with CS or CA.
• Cangrelor ensures adequate periprocedural platelet inhibition, mitigating ischemic risk when oral absorption is compromised.
• Practical guidance facilitates the effective implementation of cangrelor therapy and subsequent transition to oral P2Y12 inhibitors.